Document and Entity Information
Document and Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2017 | Mar. 28, 2018 | Jun. 30, 2017 | |
Document and Entity Information: | |||
Entity Registrant Name | HST Global, Inc. | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2017 | ||
Amendment Flag | false | ||
Entity Central Index Key | 797,564 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Common Stock, Shares Outstanding | 36,719,854 | ||
Entity Public Float | $ 0.1 | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Document Fiscal Year Focus | 2,017 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | hstc |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 | |
Current Assets | |||
Cash and cash equivalents | $ 291 | $ 465 | |
Total Current Assets | 291 | 465 | |
Total Assets | 291 | 465 | |
Current Liabilities | |||
Accounts payable and accrued expenses | 4,688 | 25,219 | |
Accounts payable and accrued expenses - related parties | 505,959 | 505,959 | |
Accrued officer compensation | 990,000 | 870,000 | |
Accrued related party interest | 35,748 | 35,748 | |
Notes payable - related party | 1,351,369 | 1,321,669 | |
Total Current Liabilities | 3,192,898 | 3,027,980 | |
Total Liabilities | 3,192,898 | 3,027,980 | |
Stockholders' Deficit | |||
Common stock | [1] | 36,720 | 36,720 |
Additional paid-in capital | 2,384,824 | 2,384,824 | |
Accumulated deficit | (5,614,151) | (5,449,059) | |
Total Stockholders' Deficit | (3,192,607) | (3,027,515) | |
Total Liabilities and Stockholders' Deficit | $ 291 | $ 465 | |
[1] | 100,000,000 shares authorized, at $0.001 par value, 36,719,854 and 36,719,854 shares issued and outstanding, respectively |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Operating Expenses: | ||
Consulting | $ 120,000 | $ 120,000 |
General and administrative | 32,995 | 17,274 |
Total Operating Expenses | 152,995 | 137,274 |
Net Loss From Operations | (152,995) | (137,274) |
Other Income (Expense) | ||
Interest expense | (35,748) | (35,748) |
Gain on forgiveness of accounts payable | (23,651) | |
Total Other Income (Expense) | (12,097) | (35,748) |
Net Loss | $ (165,092) | $ (173,022) |
Loss Per Share: Basic And Diluted - Common | $ 0 | $ 0 |
Weighted Average Shares Outstanding: Basic And Diluted - Common | 36,719,854 | 36,719,854 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) | Total | Common Stock | Additional Paid-In Capital | Accumulated deficit | Total Stockholders' Deficit |
Balance Beginning of Period at Dec. 31, 2014 | $ 36,720 | $ 2,384,824 | $ (5,080,242) | $ (2,658,698) | |
Balance Beginning of Period - Shares at Dec. 31, 2014 | 36,719,854 | ||||
Net Loss | (195,795) | (195,795) | |||
Balance End of Period at Dec. 31, 2015 | $ 36,720 | 2,384,824 | (5,276,037) | (2,854,493) | |
Balance End of Period - Shares at Dec. 31, 2015 | 36,719,854 | ||||
Net Loss | $ (173,022) | (173,022) | (173,022) | ||
Balance End of Period at Dec. 31, 2016 | $ 36,720 | 2,384,824 | (5,449,059) | (3,027,515) | |
Balance End of Period - Shares at Dec. 31, 2016 | 36,719,854 | ||||
Net Loss | $ (165,092) | (165,042) | (165,042) | ||
Balance End of Period at Dec. 31, 2017 | $ 36,720 | $ 2,384,824 | $ (5,614,151) | $ (3,192,602) | |
Balance End of Period - Shares at Dec. 31, 2017 | 36,719,854 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Cash Flows From Operating Activities: | ||
Net Loss | $ (165,092) | $ (173,022) |
Adjustments to reconcile net loss to net cash used by operating activities: | ||
Gain on forgiveness of accounts payable | (23,651) | |
Changes in operating assets and liabilities: | ||
Change in Accounts payable and accrued expenses | (3,121) | (4,656) |
Change in Accrued officer compensation | 120,000 | 120,000 |
Change in Accrued related party interest | 35,748 | 35,748 |
Net Cash used in Operating Activities | (29,874) | (21,930) |
Cash Flows From Financing Activities: | ||
Proceeds from notes payable - related party | 29,700 | 22,200 |
Net cash provided by financing activities | 29,700 | 22,200 |
Net Decrease in cash | (174) | 270 |
Cash at Beginning of Period | 465 | 195 |
Cash at End of Period | $ 291 | $ 465 |
Note 1 - Organization and Princ
Note 1 - Organization and Principal Activities | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Note 1 - Organization and Principal Activities | NOTE 1 ORGANIZATION AND PRINCIPAL ACTIVITIES HST Global, Inc. (the "Company") was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc. At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia. HST Global, Inc. is an integrated Health and Wellness Biotechnology company that is developing and/or acquiring a network of Wellness Centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases. In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases. |
Note 2 - Significant Accounting
Note 2 - Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Note 2 - Significant Accounting Policies | NOTE 2 SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with the rules and regulations of the United States Securities and Exchange Commission (SEC) to Form 10-K. Princliples of Consolidation The consolidated financial statements include our wholly-owned subsidiary. Intercompany balances and transactions have been eliminated. Accounting Method The Companys financial statements are prepared using the accrual method of accounting. The Company has elected a December 31 year-end. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Income Taxes The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC 740, " Income Taxes The Company applies the provisions of ASC 740, Accounting for Uncertainty in Income Taxes Basic and Diluted Loss Per Share The computations of basic loss per share of common stock are based on the weighted average number of shares outstanding at the date of the financial statements. The Company computes net income (loss) per share in accordance with ASC 260. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. The Company had no common stock equivalents outstanding as of December 31, 2017 and 2016. Stock-Based Compensation The Company adopted ASC 718, Stock Compensation, December 31 Fair Value of Financial Instruments The Company adopted ASC 820 which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under this standard certain assets and liabilities must be measured at fair value, and disclosures are required for items measured at fair value. The Company currently does not have non-financial assets or non-financial liabilities that are required to be measured at fair value on a recurring basis. The Companys financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. The fair value of the Companys cash is based on quoted prices and therefore classified as Level 1. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. Recently Issued Accounting Pronouncements Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys consolidated financial statements. |
Note 3 - Going Concern
Note 3 - Going Concern | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Note 3 - Going Concern | NOTE 3 GOING CONCERN The Companys consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business within one year after the date these financial statements were issued Managements plan to support the Company in its operations and to maintain its business strategy is to raise funds through public offerings and to rely on officers and directors to perform essential functions with minimal compensation. If the Company does not raise all of the money it needs from public offerings, it will have to find alternative sources, such as a second public offering, a private placement of securities, or loans from its officers, directors or others. If the Company requires additional cash and is unable to raise it, it will either have to suspend operations until the cash is raised, or cease business entirely. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. |
Accounts Payable and Accrued Li
Accounts Payable and Accrued Liabilities Disclosure | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Accounts Payable and Accrued Liabilities Disclosure | NOTE 4 ACCOUNTS PAYABLE AND ACCURED EXPENSES RELATED PARTIES Accounts payable and accrued expenses- related parties consist of the following at December 31, 2017 and 2016: December 31, 2017 December 31, 2016 The Health Network, Inc. $365,462 $365,462 Ronald Howell $43,770 $43,770 Eric Clemons $96,727 $96,727 Total $505,959 $505,959 Please see Note 6 for further explanation of these liabilities. |
Note 4 - Notes Payable - Relate
Note 4 - Notes Payable - Related Parties | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Note 4 - Notes Payable - Related Parties | NOTE 5 NOTES PAYABLE RELATED PARTIES During the year ended December 31, 2017, the Company received $29,700 in additional cash loans from various related parties. During the year ended December 31, 2016, the Company received $22,200 in additional cash loans from various related parties. Total related party notes payable as of December 31, 2017 were $1,351,369. Of this total, $595,800 of related party notes payable is unsecured, bears interest at 6 percent per annum, and is due on demand; Also of this total, $200,000 is unsecured, bears a flat owed interest amount of $46,000, and is due on demand. The remaining $555,569 of related party notes payable is unsecured, bears no interest, and is due on demand. Included in the related party notes payable balance is a $50,000 penalty fee associated with one of its related party notes due to nonpayment. |
Note 5 - Related Party Transact
Note 5 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Note 5 - Related Party Transactions | NOTE 6 RELATED PARTY TRANSACTIONS Executive Offices The Company's executive offices are located at 150 Research Dr., Hampton VA. These offices are leased by The Health Network, Inc. ("THN"), of which Ron Howell is President. THN allows the Company to use the office space without a formal sublease or rental agreement. At December 31, 2017 and 2016 Consulting Agreements The Company has entered into a consulting agreement with Mr. Howell, President of the Company, whereby the Company agreed to pay Mr. Howell $10,000 per month for consulting services through December 31, 2010. Mr. Howell received 714,286 shares of common stock valued at $120,000 as a partial payment for amounts owed under this agreement. The consulting agreement may be terminated at will by the Company. The Company intends to The Company entered into a consulting agreement with Eric Clemons, a shareholder of the Company, whereby the Company agreed to pay Mr. Clemons $10,000 per month for consulting services through December 2009. This employment agreement carried the provision that it could be extended beyond this date upon mutual agreement by both parties and that the agreement could be canceled by the Company at any time after that date. The Company continued to accrue amounts owed under this agreement through July of 2010. The balance owed to Mr. Clemons at December 31, 2017 |
Note 7 - Income Taxes
Note 7 - Income Taxes | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Note 7 - Income Taxes | NOTE 7 INCOME TAXES The Company follows ASC 740, under which deferred income taxes reflect the net effect of (a) temporary difference between carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax reporting purposes, and (b) net operating loss carry-forwards. No net provision for refundable Federal income tax has been made in the accompanying statement of loss because no recoverable taxes were paid previously. Similarly, no deferred tax asset attributable to the net operating loss carry-forward has been recognized, as it is not deemed likely to be realized. The cumulative tax effect at the expected rate of 34 percent of significant items comprising our net deferred tax amount is as follows: Year Ended December 31, 2017 Year Ended December 31, 2016 Income tax benefit attributable to: Net operating loss $ (56,131) $ (58,827) Common stock issued for services - - Change in valuation allowance 56,131 58,827 Net refundable amount $ - $ - The cumulative tax effect at the expected rate of 34 percent of significant items comprising our net deferred tax amount is as follows: December 31, 2017 December 31, 2016 Deferred tax asset attributable to: Net operating loss carry forwards $ (1,934,445) $ (1,887,314) Common stock issued for services 184,072 184,072 Valuation allowance 1,759,373 1,703,242 Net deferred tax asset $ - $ - The Companys zero percent effective tax rate for each year, as compared to the 34 percent statutory rate, results from non-deductible stock based compensation and the change in valuation allowance. At December 31, 2017, the Company had an unused net operating loss carry-forward of approximately $1,943,445 that is available to offset future taxable income; the loss carry-forward will begin to expire in 2027. |
Note 6 - Subsequent Events
Note 6 - Subsequent Events | 12 Months Ended |
Dec. 31, 2017 | |
Notes | |
Note 6 - Subsequent Events | NOTE 8 SUBSEQUENT EVENTS In accordance with ASC 855, Company management reviewed all material events through the date of this report and determined that there are no material subsequent events to report. |
Note 2 - Significant Accounti14
Note 2 - Significant Accounting Policies: Basis of Presentation (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Basis of Presentation | Basis of Presentation The accompanying financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with the rules and regulations of the United States Securities and Exchange Commission (SEC) to Form 10-K. |
Note 2 - Significant Accounti15
Note 2 - Significant Accounting Policies: Princliples of Consolidation (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Princliples of Consolidation | Princliples of Consolidation The consolidated financial statements include our wholly-owned subsidiary. Intercompany balances and transactions have been eliminated. |
Note 2 - Significant Accounti16
Note 2 - Significant Accounting Policies: Accounting Method (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Accounting Method | Accounting Method The Companys financial statements are prepared using the accrual method of accounting. The Company has elected a December 31 year-end. |
Note 2 - Significant Accounti17
Note 2 - Significant Accounting Policies: Use of Estimates (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Note 2 - Significant Accounti18
Note 2 - Significant Accounting Policies: Cash and Cash Equivalents (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Cash and Cash Equivalents | Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. |
Note 2 - Significant Accounti19
Note 2 - Significant Accounting Policies: Income Taxes (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Income Taxes | Income Taxes The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC 740, " Income Taxes The Company applies the provisions of ASC 740, Accounting for Uncertainty in Income Taxes |
Note 2 - Significant Accounti20
Note 2 - Significant Accounting Policies: Basic Loss Per Share (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Basic Loss Per Share | Basic and Diluted Loss Per Share The computations of basic loss per share of common stock are based on the weighted average number of shares outstanding at the date of the financial statements. The Company computes net income (loss) per share in accordance with ASC 260. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. The Company had no common stock equivalents outstanding as of December 31, 2017 and 2016. |
Note 2 - Significant Accounti21
Note 2 - Significant Accounting Policies: Stock-based Compensation (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Stock-based Compensation | Stock-Based Compensation The Company adopted ASC 718, Stock Compensation, December 31 |
Note 2 - Significant Accounti22
Note 2 - Significant Accounting Policies: Fair Value of Financial Instruments (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company adopted ASC 820 which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under this standard certain assets and liabilities must be measured at fair value, and disclosures are required for items measured at fair value. The Company currently does not have non-financial assets or non-financial liabilities that are required to be measured at fair value on a recurring basis. The Companys financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. The fair value of the Companys cash is based on quoted prices and therefore classified as Level 1. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. |
Note 2 - Significant Accounti23
Note 2 - Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Policies | |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys consolidated financial statements. |
Accounts Payable and Accrued 24
Accounts Payable and Accrued Liabilities Disclosure: Schedule of Accounts Payable and Accrued Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Tables/Schedules | |
Schedule of Accounts Payable and Accrued Liabilities | December 31, 2017 December 31, 2016 The Health Network, Inc. $365,462 $365,462 Ronald Howell $43,770 $43,770 Eric Clemons $96,727 $96,727 Total $505,959 $505,959 |
Note 7 - Income Taxes_ Schedule
Note 7 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Tables/Schedules | |
Schedule of Components of Income Tax Expense (Benefit) | Year Ended December 31, 2017 Year Ended December 31, 2016 Income tax benefit attributable to: Net operating loss $ (56,131) $ (58,827) Common stock issued for services - - Change in valuation allowance 56,131 58,827 Net refundable amount $ - $ - |
Note 7 - Income Taxes_ Schedu26
Note 7 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Tables/Schedules | |
Schedule of Deferred Tax Assets and Liabilities | December 31, 2017 December 31, 2016 Deferred tax asset attributable to: Net operating loss carry forwards $ (1,934,445) $ (1,887,314) Common stock issued for services 184,072 184,072 Valuation allowance 1,759,373 1,703,242 Net deferred tax asset $ - $ - |
Accounts Payable and Accrued 27
Accounts Payable and Accrued Liabilities Disclosure: Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Details | |||
Due to Affiliate, Current | $ 365,462 | $ 365,462 | $ 365,462 |
Due to Officers or Stockholders, Current | 920,000 | 800,000 | 43,770 |
Due to Other Related Parties, Current | 70,000 | 70,000 | 96,727 |
Accounts payable and accrued expenses - related parties | $ 505,959 | $ 505,959 | $ 505,959 |
Note 4 - Notes Payable - Rela28
Note 4 - Notes Payable - Related Parties (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Details | ||
Proceeds from notes payable - related party | $ 29,700 | $ 22,200 |
Notes payable - related party | $ 1,351,369 | $ 1,321,669 |
Note 5 - Related Party Transa29
Note 5 - Related Party Transactions (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Details | |||
Due to Affiliate, Current | $ 365,462 | $ 365,462 | $ 365,462 |
Due to Officers or Stockholders, Current | 920,000 | 800,000 | 43,770 |
Due to Other Related Parties, Current | $ 70,000 | $ 70,000 | $ 96,727 |
Note 7 - Income Taxes_ Schedu30
Note 7 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Income Tax Expense (Benefit), Continuing Operations | ||
Current Income Tax Expense (Benefit) | $ (56,131) | $ (58,827) |
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | $ 56,131 | $ 58,827 |
Note 7 - Income Taxes_ Schedu31
Note 7 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Deferred Tax Assets, Net | ||
Deferred Tax Assets, Operating Loss Carryforwards | $ (1,934,445) | $ (1,887,314) |
Deferred Tax Assets, Valuation Allowance | $ 1,759,373 | $ 1,703,242 |